Únase a getAbstract para acceder al resumen.

Medical Centers Spearhead China’s Pharma Push

Únase a getAbstract para acceder al resumen.

Medical Centers Spearhead China’s Pharma Push

Nation hopes reforms will yield more and better drugs

Science,

5 mins. de lectura
3 ideas fundamentales
Texto disponible

¿De qué se trata?

China has been lagging behind other nations in the global drug development race. But it is getting ready to catch up.

Editorial Rating

8

Recommendation

China has been more of a spectator than an active participant in the global drug development arena. Its biomedical research has lacked funds and innovation, and very few results are being translated into clinical use. Science magazine’s Asia correspondent Dennis Normile looks at the problems that Chinese biomedical research has been facing and what measures Chinese authorities are putting into place to kickstart innovation. getAbstract recommends this concise and informative overview to anyone who needs or wants to know the direction Chinese biomedical research and drug development is heading.

Summary

​​​​​​China has lagged behind other nations in the field of biomedical research.

China’s biomedical research and its ability to translate research results into real-world applications has been floundering for a while. The first problem lies with research and development (R&D). R&D only plays a relatively small role in China’s pharma industry. Clinicians have to deal with massive patient loads and do not have much time left for non-clinical research. Academics need to publish in peer-reviewed journals at high rates. Also, the current drug review process...

About the Author

Dennis Normile is the Asia correspondent for Science magazine. He writes about research and science policy development, in particular in China and Japan.

Comment on this summary